Humira licensed for use in ankylosing spondylitis

The recombinant human monoclonal antibody Humira (adalimumab) has been approved for the treatment of severe active ankylosing spondylitis in adult patients who have not responded adequately to conventional therapy.

The recommended dose of Humira in ankylosing spondylitis is 40mg administered every other week as a single dose via subcutaneous injection.

In clinical trials, a significant improvement in the condition was seen after 2 weeks of treatment and was maintained through the 24 weeks of the study.

Further information: Abbott Laboratories Ltd, Norden Road, Maidenhead, Berks SL6 4XE. Tel: (01628) 773355.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases